1 Pennathur, A., Gibson, M. K., Jobe, B. A. & Luketich, J. D. Oesophageal carcinoma. Lancet 381, 400-412, doi:10.1016/S0140-6736(12)60643-6 (2013).
2 Patel, N. & Benipal, B. Incidence of Esophageal Cancer in the United States from 2001-2015: A United States Cancer Statistics Analysis of 50 States. Cureus 10, e3709, doi:10.7759/cureus.3709 (2018).
3 Howlader N, N. A., Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA. SEER Cancer Statistics Review, 1975-2017, < https://seer.cancer.gov/csr/1975_2016/> (2020).
4 Lagergren, J., Smyth, E., Cunningham, D. & Lagergren, P. Oesophageal cancer. Lancet 390, 2383-2396, doi:10.1016/S0140-6736(17)31462-9 (2017).
5 van Putten, M. et al. Long-term survival improvement in oesophageal cancer in the Netherlands. Eur J Cancer 94, 138-147, doi:10.1016/j.ejca.2018.02.025 (2018).
6 Berry, M. F. Esophageal cancer: staging system and guidelines for staging and treatment. J Thorac Dis 6 Suppl 3, S289-297, doi:10.3978/j.issn.2072-1439.2014.03.11 (2014).
7 Meves, V., Behrens, A. & Pohl, J. Diagnostics and Early Diagnosis of Esophageal Cancer. Viszeralmedizin 31, 315-318, doi:10.1159/000439473 (2015).
8 Shaheen, O., Ghibour, A. & Alsaid, B. Esophageal Cancer Metastases to Unexpected Sites: A Systematic Review. Gastroenterol Res Pract 2017, 1657310, doi:10.1155/2017/1657310 (2017).
9 Zhang, Y. Epidemiology of esophageal cancer. World J Gastroenterol 19, 5598-5606, doi:10.3748/wjg.v19.i34.5598 (2013).
10 Dhupar, R. et al. Endoscopic Ultrasound Estimates for Tumor Depth at the Gastroesophageal Junction Are Inaccurate: Implications for the Liberal Use of Endoscopic Resection. Ann Thorac Surg 100, 1812-1816, doi:10.1016/j.athoracsur.2015.05.038 (2015).
11 Bird-Lieberman, E. L. & Fitzgerald, R. C. Early diagnosis of oesophageal cancer. Br J Cancer 101, 1-6, doi:10.1038/sj.bjc.6605126 (2009).
12 Smyth, E. C. et al. Oesophageal cancer. Nat Rev Dis Primers 3, 17048, doi:10.1038/nrdp.2017.48 (2017).
13 Abbas, G. & Krasna, M. Overview of esophageal cancer. Ann Cardiothorac Surg 6, 131-136, doi:10.21037/acs.2017.03.03 (2017).
14 Rustgi, A. K. & El-Serag, H. B. Esophageal carcinoma. N Engl J Med 371, 2499-2509, doi:10.1056/NEJMra1314530 (2014).
15 Sasaki, Y. & Kato, K. Chemoradiotherapy for esophageal squamous cell cancer. Jpn J Clin Oncol 46, 805-810, doi:10.1093/jjco/hyw082 (2016).
16 Lee, P. C. et al. Predictors of recurrence and disease-free survival in patients with completely resected esophageal carcinoma. J Thorac Cardiovasc Surg 141, 1196-1206, doi:10.1016/j.jtcvs.2011.01.053 (2011).
17 Matsushita, D. et al. Clinical Significance of Circulating Tumor Cells in Peripheral Blood of Patients with Esophageal Squamous Cell Carcinoma. Ann Surg Oncol 22, 3674-3680, doi:10.1245/s10434-015-4392-8 (2015).
18 Reeh, M. et al. Circulating Tumor Cells as a Biomarker for Preoperative Prognostic Staging in Patients With Esophageal Cancer. Ann Surg 261, 1124-1130, doi:10.1097/SLA.0000000000001130 (2015).
19 Cohen, J. D. et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 359, 926-930, doi:10.1126/science.aar3247 (2018).
20 Azad, T. D. et al. Circulating Tumor DNA Analysis for Detection of Minimal Residual Disease After Chemoradiotherapy for Localized Esophageal Cancer. Gastroenterology 158, 494-505 e496, doi:10.1053/j.gastro.2019.10.039 (2020).
21 Kilic, A. et al. Use of novel autoantibody and cancer-related protein arrays for the detection of esophageal adenocarcinoma in serum. J Thorac Cardiovasc Surg 136, 199-204, doi:10.1016/j.jtcvs.2008.01.012 (2008).
22 Chen, M., Huang, J., Zhu, Z., Zhang, J. & Li, K. Systematic review and meta-analysis of tumor biomarkers in predicting prognosis in esophageal cancer. BMC Cancer 13, 539, doi:10.1186/1471-2407-13-539 (2013).
23 van den Boorn, H. G. et al. Prediction models for patients with esophageal or gastric cancer: A systematic review and meta-analysis. PLoS One 13, e0192310, doi:10.1371/journal.pone.0192310 (2018).
24 Adams, D. et al. Cancer-associated macrophage-like cells as prognostic indicators of overall survival in a variety of solid malignancies. Journal of Clinical Oncology 35, 11503-11503, doi:10.1200/JCO.2017.35.15_suppl.11503 (2017).
25 Adams, D. L. et al. Circulating giant macrophages as a potential biomarker of solid tumors. Proc Natl Acad Sci U S A 111, 3514-3519, doi:10.1073/pnas.1320198111 (2014).
26 Manjunath, Y. et al. Circulating giant tumor-macrophage fusion cells are independent prognosticators in non-small cell lung cancer patients. J Thorac Oncol, doi:10.1016/j.jtho.2020.04.034 (2020).
27 Adams, D. et al. Sequential monitoring of CAMLs in circulation as predictive of progression in lung cancer patients undergoing definitive radiotherapy. Journal of Clinical Oncology 36, e21062-e21062, doi:10.1200/JCO.2018.36.15_suppl.e21062 (2018).
28 Adams, D. L. et al. The systematic study of circulating tumor cell isolation using lithographic microfilters. RSC Adv 9, 4334-4342, doi:10.1039/C3RA46839A (2014).
29 Lin, E. W., Karakasheva, T. A., Hicks, P. D., Bass, A. J. & Rustgi, A. K. The tumor microenvironment in esophageal cancer. Oncogene 35, 5337-5349, doi:10.1038/onc.2016.34 (2016).
30 Teresa Pinto, A. et al. Ionizing radiation modulates human macrophages towards a pro-inflammatory phenotype preserving their pro-invasive and pro-angiogenic capacities. Sci Rep 6, 18765, doi:10.1038/srep18765 (2016).